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Early-onset metabolic syndrome in mice lacking the
intestinal uric acid transporter SLC2A9
Brian J. DeBosch1, Oliver Kluth2, Hideji Fujiwara1, Annette Schu¨rmann2 & Kelle Moley1
Excess circulating uric acid, a product of hepatic glycolysis and purine metabolism, often
accompanies metabolic syndrome. However, whether hyperuricaemia contributes to the
development of metabolic syndrome or is merely a by-product of other processes that cause
this disorder has not been resolved. In addition, how uric acid is cleared from the circulation is
incompletely understood. Here we present a genetic model of spontaneous, early-onset
metabolic syndrome in mice lacking the enterocyte urate transporter Glut9 (encoded by the
SLC2A9 gene). Glut9-deﬁcient mice develop impaired enterocyte uric acid transport kinetics,
hyperuricaemia, hyperuricosuria, spontaneous hypertension, dyslipidaemia and elevated
body fat. Allopurinol, a xanthine oxidase inhibitor, can reverse the hypertension and
hypercholesterolaemia. These data provide evidence that hyperuricaemia per se could have
deleterious metabolic sequelae. Moreover, these ﬁndings suggest that enterocytes may
regulate whole-body metabolism, and that enterocyte urate metabolism could potentially be
targeted to modulate or prevent metabolic syndrome.
DOI: 10.1038/ncomms5642
1 BJC Institute of Health, Washington University School of Medicine, 10th Floor 425 S., Euclid Avenue Campus, Box 8064, St Louis, MO 63110, USA.
2Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal 14558, Germany. Correspondence and
requests for materials should be addressed to K.M. (email: moleyk@wudosis.wustl.edu).
NATURE COMMUNICATIONS | 5:4642 |DOI: 10.1038/ncomms5642 | www.nature.com/naturecommunications 1
& 2014 Macmillan Publishers Limited. All rights reserved.
M
etabolic syndrome is a complex multifactorial disease
that afﬂicts two in ﬁve adults in the U.S. alone1, and
scores more worldwide. Observations over the prior
two decades demonstrated increased metabolic syndrome, type 2
diabetes mellitus and cardiovascular morbidity in hyperuricaemic
subjects2,3, and that serum uric acid levels independently predict
diabetes, fatty liver and metabolic syndrome2. Work in rodent
models further mechanistically implicated uric acid in fructose-
induced metabolic syndrome4, although some controversy over
the exact physiological function of urate (the predominant form
of uric acid at physiological pH) remains5,6. Elucidating how
urate is removed from the circulation may nevertheless have
broad individual and public health implications.
Approximately 60–70% of circulating uric acid clearance
occurs in the kidney and the other 30–40% is cleared via
intestinal enterocytes7, although the enterocyte may become the
primary excretory pathway in renally insufﬁcient patients8 (for
example, in patients with diabetes, hypertension or cardiorenal
disease). Recent data suggest that defective extrarenal clearance is
a common cause of hyperuricemia9, yet few studies address
enterocyte urate-handling mechanisms9–11, and none address
endogenous urate clearance mechanisms as effectors of
mammalian metabolism. The putative enterocyte urate
transporters—BCRP/ABCG2 (and potentially SLC17A4/NPT5)
are apical transporters10,11, whereas a basolateral transporter has
not been identiﬁed. Therefore, it was unresolved how uric acid
ﬂux occurred down its gradient from the blood into the
enterocyte cytoplasm before excretion in the stool.
Recent data in humans and in rodents identiﬁed GLUT9/Glut9
as a high-capacity urate transporter12,13, the deletion of which
alters urate homeostasis in a tissue-speciﬁc manner14,15.
Furthermore, Glut9 is a basolateral and apical membrane
transporter in other polarized epithelial cell types12. Thus, we
examined GLUT9 localization, cellular function and role in urate
homeostasis in the murine intestine.
Here we show that Glut9 is localized to the apical and
basolateral enterocyte membranes, and that enterocyte-speciﬁc
Glut9 deﬁciency impairs enterocyte urate transport. Concomitant
with these urate clearance defects, enterocyte Glut9-deﬁcient mice
develop hyperuricaemia, hyperuricosuria and early-onset meta-
bolic syndrome—hypertension, dyslipidaemia, hyperinsulinaemia
and hepatic fat deposition—which is partly mitigated by ad lib
administration of the xanthine oxidase inhibitor, allopurinol.
These results suggest that Glut9 regulates enterocyte urate
clearance, and that enterocyte Glut9 deﬁciency may have
deleterious metabolic sequelae.
Results
Expression and localization of enterocyte Glut9. Immunoblot
analysis demonstrated that Glut9 was abundantly expressed in
intestine (Fig. 1a), highly in the jejunum and ileum (Fig. 1b), the
segments of the intestine that perform the majority of urate
excretion8,10. Confocal immunoﬂuorescence microscopy of ﬁxed
mouse intestine revealed Glut9 localized predominantly to the
basolateral enterocyte membrane with some apical staining
(Fig. 1c).
Generation of mice lacking enterocyte Glut9. Given that Glut9
is the only reported basolateral urate transporter, we hypothe-
sized that mice lacking Glut9 in enterocytes would have impaired
enteric urate handling. We thus generated enterocyte-speciﬁc
Glut9-deﬁcient mice by crossing mice harbouring a ﬂoxed
SLC2A9 allele with mice overexpressing cre recombinase driven
by the enterocyte-speciﬁc villin promoter (Fig. 1d,e). vil-Cre/
SLC2A9ﬂ/ﬂ (G9EKO) mice were live-born in Mendelian ratios,
were fertile and had no gross morphologic defects (Table 1).
Immunoblotting conﬁrmed deﬁciency of total Glut9A and total
Glut9 protein in G9EKO small-bowel lysates (Fig. 1f and
Supplementary Figs 1 and 2). Isolated villous enterocytes from
G9EKO mice exhibited an B65% [14C]-urate uptake defect
versus wild-type (WT) enterocytes when compared with mice
expressing vil-Cre with WT SLC2A9 alleles (hereafter referenced
as ‘WT’ mice) (Fig. 1g). Congruent with these ﬁndings, liquid
chromatography–mass spectrometry (LC/MS) of stool extracts
revealed signiﬁcantly decreased stool urate concentrations in
G9EKO mice versus WT mice (Fig. 1h). Together, these results
suggested impaired enterocyte uptake and efﬂux into stool in
G9EKO animals.
Physiological consequences of impaired enterocyte urate
clearance. We next examined physiological consequences of
impaired enterocyte urate efﬂux in mice fed standard rodent
chow (Picolab #5053: 25% protein, 13% fat and 62% carbohy-
drate). Uricase-based urate determinations further revealed
signiﬁcantly higher uric acid concentrations in both serum and
urine in G9EKO mice (Fig. 2a,b). Body composition analysis by
EchoMRI revealed signiﬁcantly elevated body fat mass and
fat percentage (Fig. 2c,d) despite higher resting energy expendi-
ture as determined by indirect calorimetry in G9EKO mice
(Table 2). Plasma analysis revealed G9EKO mice had signiﬁcantly
elevated total cholesterol, free fatty acids and triglycerides
(Fig. 2e–g). Some evidence of early insulin resistance was
observed, with an approximately 40% elevation in fasting plasma
insulin in G9EKO mice (Fig. 2h) in context of normal fasting
blood glucose (Fig. 2i) and insulin tolerance testing (Fig. 2j). Tail-
cuff plethysmography in unanaesthetized G9EKO mice demon-
strated signiﬁcant baseline hypertension when compared with
WT mice (Fig. 2k).
We next assessed whether blocking uric acid production
could reverse any of these effects of impaired urate clearance. WT
and G9EKO mice were thus exposed to 8-week allopurinol
(150mg l 1) ad libitum in sterilized drinking water approxi-
mately 4 weeks after weaning4. Plasma uric acid was signiﬁcantly
decreased in G9EKO mice following allopurinol treatment
without signiﬁcant effects on urine urate concentrations
(Fig. 3a,b). Strikingly, in comparison with untreated G9EKO
mice, allopurinol treatment also lowered blood pressure and total
cholesterol (Fig. 3c,d) without signiﬁcant effects on free fatty
acids and triglycerides suggesting at least partial allopurinol
reversibility of the spontaneous metabolic syndrome in G9EKO
mice—either through xanthine oxidase inhibition or through
direct effects on renal uric acid transporters by allopurinol or
by its active metabolite, oxypurinol. Fasting free fatty acid
and triglyceride were not signiﬁcantly affected by allopurinol
(Fig. 3e,f).
We then looked at well-described secondary complications of
hyperuricaemia in G9EKO mice, including non-alcoholic fatty
liver disease and cardiovascular disease. Consistent with ﬁndings
of increased steatosis/non-alcoholic fatty liver disease in patients
with hyperuricaemia16, hepatic triglycerides and free fatty acids
were elevated in G9EKO livers versus WT livers (Fig. 4a,b). In
addition, mRNA for sterol regulatory element-binding protein, a
marker of cholesterol metabolism, was signiﬁcantly elevated in
the livers of G9EKO mice, and there was a trend toward elevated
collagen type 1 alpha and fatty acid synthase, markers of ﬁbrosis
and fat synthesis.
The increased incidence of cardiovascular morbidity in
hyperuricaemic patients prompted us to survey the cardiac
phenotype of G9EKO mice. Basal heart rate observed by
echocardiography was signiﬁcantly elevated in G9EKO mice
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Figure 1 | Characterization of intestinal Glut9 and genetic deletion of enterocyte SLC2A9. (a) Immunoblotting against full-length Glut9 in murine tissue.
(b) Small-bowel segment-speciﬁc Glut9 immunoblotting. (c) Left, confocal immunoﬂuorescence microscopy demonstrating basolateral and apical Glut9
localization in duodenum and jejunum. Middle, jejunal immunostaining with pre-immune serum. Scale bar, 10 mm. Right, speciﬁcity of total Glut9 antiserum
versus pre-immune serum by liver and kidney lysate immunoblotting (d) Glut9-targeting construct used to generate mice harbouring ﬂoxed SLC2A9
ﬂanking exons 5 and 6. Forward and reverse (for/rev) genotyping primers ﬂank the ﬂox site adjacent to exon 5. (e) PCR bands depicting larger ﬂoxed
(720 bp) and wild-type (WT) (554bp) sequences. (f) Immunoblot of Glut9A in WT and G9EKO mouse whole intestine, liver and kidney lysate.
(g) [14C]-uric acid uptake in puriﬁed villous enterocyte fractions from WT and G9EKO mice. n¼ 5 per group. In vitro experiment replicated thrice.
*Po0.05 versus WT (two-tailed t-testing). Error bars represent s.e.m. (h) LC/MS analysis of stool from WT and G9EKO mice. Upper spectra—uric
acid (arrows) elution. Lower spectra (arrowheads)—1-methyluric acid internal standard. Experiment replicated thrice.
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(Fig. 4d). Echocardiogram also revealed evidence of cardiac
hypertrophic remodelling, (Fig. 4e,f)—decreased diastolic left
ventricular internal diameter with increased relative wall
thickness—a common ﬁnding in patients with hyperuriceamia17.
However, although allopurinol treatment signiﬁcantly lowered
body weight (Fig. 5a) and hepatic triglyceride content (Fig. 5c)
associated with a trend toward lower body fat mass in G9EKO
mice (Fig. 1b), allopurinol treatment did not signiﬁcantly reverse
the G9EKO-associated changes in heart rate, left ventricular
internal diameter or relative wall thickness (Fig. 5d–f).
Discussion
Mice lacking enterocyte Glut9 thus develop early-onset sponta-
neous hyperuricaemic metabolic syndrome that is partially
mitigated by allopurinol, a xanthine oxidase inhibitor. Not all
deleterious ﬁndings in the G9EKO model were reversed by
allopurinol, suggesting either (a) some metabolic syndrome
components occur independently of hyperuricaemia, (b) some
metabolic syndrome components caused by hyperuricaemia are
irreversible once clinically apparent or (c) uric acid is unrelated to
any ﬁndings, and the allopurinol effects are derived speciﬁcally
from blocking oxidant production via xanthine oxidase inhibition
per se. It should be noted, however, that the key advantage to this
model of impaired urate excretion in delineating the speciﬁc
Table 1 | Basic morphometric parameters in wild-type (WT)
and G9EKO mice.
n BW LW HW LW/BW HW/BW
Wild type 19 24.9 952.5 132.2 39.3 5.5
G9EKO 10 26.1 922.2 129.9 40.1 5.7
P-value — 0.116 0.585 0.741 0.634 0.439
BW, body weight; HW, heart weight; LW, liver weight.
P-values are derived from two-tailed t-tests.
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Figure 2 | Physiological consequences of enterocyte Glut9 deﬁciency. (a,b) Serum (n¼9, 16) and urine (n¼ 13, 12) uric acid concentration in
fasting 6–8-week-old mice. (c,d) EchoMRI analysis of fat mass and percentage fat (n¼ 19, 10). (e–i) Plasma cholesterol (n¼6, 5), triglycerides,
free fatty acids, insulin (n¼ 5, 4) and glucose in fasting WTand G9EKO mice. (j) Insulin tolerance testing in 4-h fasting mice (n¼ 6, 22). (k) Systolic (SBP),
diastolic (DBP) and mean (MBP) blood pressure in non-fasting WT mice and G9EKO (n¼ 9, 17). *Po0.05, **Po0.01 and ***Po0.001 versus WT
(two-tailed t-testing). Error bars represent s.e.m.
Table 2 | Indirect calorimetric data from 8- and 16-week-old
wild type and G9EKO mice.
n VO2
(ml g 1 h 1)
VCO2







9 9.14 7.55 0.83 0.81
9EKO
(8 week)
12 10.24* 7.44 0.74* 1.17*
Wild type
(16 week)
10 8.61 7.32 0.86 0.99
9EKO
(16 week)
12 9.07* 7.27 0.81 0.97
RER, respiratory exchange ratio; VCO2, volume of expired carbon dioxide; VO2, volume of
inspired oxygen.
*Po0.05 versus age-matched wild-type control, as determined by two-tailed t-tests.
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effects of hyperuricaemia is that it does not rely on xanthine
oxidase activity to produce hyperuricaemia as in some of the diet-
induced models (for example, fructose- or purine-rich diets).
Nevertheless, while further insight into the effects of hyperur-
icaemia on its host are required, the G9EKO model suggests that
attenuated enterocyte urate clearance could be a critical, initiating
step in metabolic syndrome pathogenesis. Interdicting circulating
urate accumulation by focusing on gut urate reuptake and
clearance could represent a novel treatment paradigm to block or
modulate hyperuricaemia and its complications, including
metabolic syndrome. We expect this model can now be used to
probe mechanistically into the role of urate in the complications
and sequelae of metabolic syndrome.
Methods
Generation of G9EKO Mice. Enterocyte-speciﬁc Glut9-deﬁcient mice were
generated by homologous recombination of the 18.9 kb targeting vector harbouring
loxP sites ﬂanking exons 5 and 6 and a neomycin resistance cassette 30 of exon 6.
Modiﬁed embryonic stem cells from 129Sv mice carrying this targeting allele were
introduced into C57BL/6 blastocysts. Chimeric offspring were twice backcrossed
into the C57BL/6 line to generate N2 mice heterozygous for the targeting allele
(genotype Slc2a9ﬂ/þ ). N2 mice were intercrossed to generate homozygous
(Slc2a9ﬂ/ﬂ) mice. Genotyping primers were as follows (listed 50–30): forward
primer—50-TGGTGCTACTCTGTGGTGCTA-30 ; reverse primer—50-CACAGCG
GTGAAAGTAACGA-30. Mice harbouring homozygous ﬂoxed Slc2a9 alleles were
crossed with mice expressing Cre recombinase under the mouse villin 1 promoter
on a C57/BL6 background (Jackson Laboratories, stock number 004586) to
generate G9EKO mice. Mice expressing villin promoter-driven Cre with WT Slc2a9
alleles were used as control mice throughout these studies. For allopurinol treat-
ment experiments, 8-week-old mice were maintained on 150mg l 1 allopurinol4
for 8 weeks before metabolic characterization. All animal procedures were
approved by the Washington University School of Medicine Animal Studies
Committee.
Calorimetry body composition and blood pressure determination. Indirect
calorimetry, echoMRI and blood pressure analyses on unanaesthetized mice
were performed via the Mouse Diabetic Models Phenotyping Core Facility at
Washington University using an Oxymax Indirect Calorimeter (Columbus
Instruments, Columbus, OH, USA), an EchoMRI 3–1 (Echo Medical Systems,
Houston, TX, USA18,19 and a Columbus Instruments NIBP (Columbus) tail-cuff
and plethysmograph. Food consumed in mice was measured in 24-h increments
during each calorimetry run.
Radiolabelled uric acid uptake measurements. Apical villous enterocytes ﬁrst
were enriched by calcium chelation and mechanical disruption20. Brieﬂy, sections
of distal jejunum (5–6 cm) were removed, ﬂushed with ice-cold phosphate-buffered
saline and opened longitudinally before immersion in ice-cold phosphate-buffered
saline. The bowel was transferred into 5ml ice-cold balanced salt solution (BSS)
buffer (1.5mM KCl, 96mM NaCl, 27mM sodium citrate, 8mm KH2PO4, 5.6mM
Na2HPO4, 15mM EDTA, and 1mM dithiothreitol) and vortexed at 4 C at
maximum speed for 20min. Following this step, almost all epithelial cells were
recovered in the BSS solution. The BSS solution (containing crypts and villi) was
ﬁltered through a 70-mm cell strainer (BD Biosciences, San Jose, CA, USA). The
larger size villi were captured in the cell strainer whereas crypts were discarded in
the efﬂuent. Crypt fractions were then spun down at 1,000g for 10min at 4 C and
washed once with Tris buffer (150mM NaCl, 1mM EDTA, 1mM EGTA, 50mM
Tris-HCl, pH 8.0) then with ice-cold DMEM before assay. To assay uptake, cells
were resuspended in pre-warmed, 37 C DMEM containing 1 mCiml 1 [14C]-uric
acid (American Radiolabeled Chemicals, St Louis, MO, USA) for 3min before
quenching and three wash steps in ice-cold Hank’s balanced salt solution. Samples
were subjected to liquid scintillation counting and counts were normalized to
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a b c d e f
Figure 3 | Allopurinol mitigates G9EKO hyperuricaemia, hypertension and dyslipidaemia. (a,b) Serum (n¼ 8, 18, 8) and urine uric acid (n¼4, 7, 7)
in WT and G9EKO fed sterile water or water containing allopurinol. (c) Systolic (SBP), diastolic (DBP) and mean (MBP) blood pressure in unmedicated
or in allopurinol-treated G9EKO and WTmice (n¼ 5, 9, 7). (d–f) Fasting cholesterol (n¼6, 5, 8), free fatty acid (FFA) (n¼ 5, 5, 5) and triglyceride
(TG) (n¼ 5, 5, 10) in WT and G9EKO mice. *Po0.05 versus WT. #Po0.05 versus untreated G9EKO mice (two-tailed t-testing with Bonferroni–Dunn
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Figure 4 | Early-onset non-alcoholic fatty liver disease (NAFLD) and cardiac remodeling in G9EKO mice. (a,b) Hepatic free fatty acid (FFA)
(n¼6, 6) and triglyceride (TG) (n¼6, 6) in WT and G9EKO liver homogenates. (c) Relative mRNA abundance of collagen type 1a, fatty acid synthase
and sterol response element-binding protein-1 by quantitative reverse transcriptase (qRT–PCR) analysis. (d–f) Echocardiographic analysis of heart rate,
diastolic left ventricular internal diameter and relative wall thickness in WT and G9EKO mice (n¼ 5, 5). *Po0.05 versus WT. ***Po0.001 versus WT
(two-tailed t-testing). Error bars represent s.e.m.
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Western Blotting and immunostaining. Western blotting was performed
using 50–100 mg protein subjected to 10% SDS–PAGE, followed by transfer to
nitrocellulose membrane and overnight primary antibody incubation21,22 (1:1,000
dilutions at 4 C) with the following antisera: total Glut9, glyceraldehyde
3-phosphate dehydrogenase (clone 14C10, Cell Signaling Technologies, Beverly,
MA, USA), Glut9A12 Actin (clone C4, EMD Millipore, Billerica, MA, USA). Fixed
(4% paraformaldehyde), parafﬁn-embedded intestinal sections were sectioned,
permeablized in 0.1% Triton X-100 in phosphate-buffered saline and blocked with
2% bovine serum albumin (Sigma-Aldrich, St Louis, MO, USA) before
immunostaining using pre-immune serum or GLUT9-speciﬁc antibody (Generated
in the laboratory of Dr Annette Schu¨rmann) at a 1:200 dilution.
LC and tandem mass spectrometry. Uric acid analysis in stool was performed by
the Washington University Metabolomics Facility. Uric acid was extracted from
B20mg dried, pulverized, sieved mouse stool using water containing 1-methyluric
acid (Sigma) for LC/MS/MS using a modiﬁed US analysis method22. 1-methyluric
acid was chosen as the internal standard and a Thermo betasil LC column was used
for negative ion electrospray LC/MS/MS analysis.
Hepatic lipid extraction. Hepatic lipids were extracted by homogenizing 100mg
of liver tissue in 2ml (2:1) chloroform:methanol23. Remaining tissue was pelleted
by centrifugation and 10–20 ml supernatant aliquots were dried for 2 h before
resuspension in assay reagent. Values were normalized to tissue input mass.
Biochemical analyses. Serum and urine uric acid, serum and hepatic cholesterol,
triglyceride, free fatty acid and serum insulin were measured using the following
kits precisely per the manufacturer’s instructions18,19,23: Amplex Red Uric Acid
Assay Kit (Invitrogen, Carlsbad, CA, USA), Inﬁnity Cholesterol Assay Kit,
(Thermo Scientiﬁc, Waltham, MA, USA), Inﬁnity triglyceride assay kit (Thermo
Scientiﬁc, Waltham, MA, USA), NEFA free fatty acid determination kit (Wako
Diagnostics, Richmond, VA, USA) and rat/mouse insulin ELISA assay kit
(Millipore, Billerica, MA, USA).
Echocardiography. Echocardiography was performed by the Washington
University Mouse Cardiovascular Phenotyping Core Facility21. Non-invasive
transthoracic cardiac ultrasound exams were performed under light general
anaesthesia using a VisualSonics Vevo 2100 cardiac echocardiography machine
with a 15-MHz linear transducer.
Statistical analysis. All values are expressed as the mean±s.e.m. Two-tailed
t-tests were applied with Bonnferroni–Dunn post hoc correction for multiple
comparisons. Po0.05 was considered to be statistically signiﬁcant between groups.
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Figure 5 | Allopurinol reduces body weight and hepatic triglycerides in
G9EKO mice. Shown is the effect of B8-week allopurinol treatment
(150mg l 1 fed ad libitum in water) on (a) body weight and (b) body fat
(n¼ 21, 19, 24) and (c) hepatic triglycerides (triglyceride (TG), n¼ 11, 9, 7).
Panels d,e,f, demonstrate the effect of allopurinol on echocardiographic
parameters (n¼ 12, 6, 12). HR, heart rate, LVIDd, internal left ventricular
diameter in diastole, RWT, relative wall thickness. *Po0.05 versus WT
control by two-tailed t-test after Bonferroni–Dunn post hoc correction for
multiple comparisons. ###Po0.001 versus untreated G9EKO mice. NS, not
statistically signiﬁcantly different versus G9EKO untreated mice (two-tailed
t-test after Bonferroni–Dunn post hoc correction). Error bars represent
s.e.m.
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